142 related articles for article (PubMed ID: 30146594)
21. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer.
Park SB; Choi JY; Moon SH; Yoo J; Kim H; Ahn YC; Ahn MJ; Park K; Kim BT
Cancer Imaging; 2014 Apr; 14(1):2. PubMed ID: 25609313
[TBL] [Abstract][Full Text] [Related]
23. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis.
Lu YY; Chen JH; Liang JA; Chu S; Lin WY; Kao CH
Nucl Med Commun; 2014 Jul; 35(7):697-703. PubMed ID: 24694775
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer.
Arslan N; Tuncel M; Kuzhan O; Alagoz E; Budakoglu B; Ozet A; Ozguven MA
Ann Nucl Med; 2011 Jul; 25(6):406-13. PubMed ID: 21409347
[TBL] [Abstract][Full Text] [Related]
26. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer.
Lee YJ; Cho A; Cho BC; Yun M; Kim SK; Chang J; Moon JW; Park IK; Choi HJ; Kim JH
Clin Cancer Res; 2009 Apr; 15(7):2426-32. PubMed ID: 19318478
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
[TBL] [Abstract][Full Text] [Related]
28. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer.
Zhao DS; Valdivia AY; Li Y; Blaufox MD
Semin Nucl Med; 2002 Oct; 32(4):272-5. PubMed ID: 12524651
[TBL] [Abstract][Full Text] [Related]
29. FDG uptake in the chest wall of a patient with small-cell lung cancer.
Stigt JA; Boomsma MF; van Bemmel BC
J Thorac Oncol; 2013 Jun; 8(6):806-7. PubMed ID: 23676559
[No Abstract] [Full Text] [Related]
30. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
31. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
[TBL] [Abstract][Full Text] [Related]
32. PET and PET-CT of lung cancer.
Steinert HC
Methods Mol Biol; 2011; 727():33-51. PubMed ID: 21331927
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of pre-treatment
Aktan M; Koc M; Kanyilmaz G; Yavuz BB
Ann Nucl Med; 2017 Jul; 31(6):462-468. PubMed ID: 28516335
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
[TBL] [Abstract][Full Text] [Related]
35. The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels.
Li W; Yin W; Ou R; Chen T; Xiong L; Cheng D; Xie D; Zheng X; Xu Y; Zhao L
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):675-81. PubMed ID: 26497700
[TBL] [Abstract][Full Text] [Related]
36. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Kaseda K; Asakura K; Kazama A; Ozawa Y
World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer.
Nobashi T; Koyasu S; Nakamoto Y; Kubo T; Ishimori T; Kim YH; Yoshizawa A; Togashi K
Br J Radiol; 2016; 89(1059):20150618. PubMed ID: 26756811
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological study of small lung cancer (diameter of 2 cm or less) by uptake value of 18F-fluorodeoxyglucose].
Nakano T; Endo S; Mitsuda S; Endo T; Tezuka Y; Kanai Y; Otani S; Yamamoto S; Tetsuka K; Hasegawa T; Ishikawa S; Saito N
Kyobu Geka; 2012 Jan; 65(1):21-4. PubMed ID: 22314152
[TBL] [Abstract][Full Text] [Related]
40. The role of positron emission tomography in management of small cell lung cancer.
Thomson D; Hulse P; Lorigan P; Faivre-Finn C
Lung Cancer; 2011 Aug; 73(2):121-6. PubMed ID: 21524814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
